Objectives: Prostate cancer is the most frequently diagnosed cancer among men, with Latino patients experiencing higher cancer-specific mortality compared to non-Hispanic populations. We evaluated prostate cancer outcomes across distinct Latino subpopulations. Methods: We retrospectively reviewed a single tertiary comprehensive cancer center database of patients with localized prostate cancer treated with radical prostatectomy from 2003 through 2020. Latino patients were subcategorized as Mexican, South/Central American (SCA), or Caribbean (Puerto Rico and Cuba). Non-Hispanic White (NHW) patients served as the reference group. Results: Overall, 7084 patients were included, of which 78% (n = 5518) were NHW and 10% (n = 679) were Latinos. Compared to NHW, Latino patients were younger at the time of surgery (median 62 vs. 64 years) and had higher median BMI (median 28.8 vs. 27.5 kg/m2), median baseline PSA (6.2 vs. 5.5 ng/mL), and D'Amico intermediate- (44% vs. 42%) and high-risk disease rates (16% vs. 13%) (all p < 0.001). Among Latino patients, Mexican patients had higher median baseline PSA (6.7 vs. 6.1 vs. 6.1 ng/mL, p = 0.005) compared to SCA and Caribbean patients. Survival analysis revealed shorter 5-year (97% vs. 99%) and 10-year (89% vs. 96%) overall survival (OS) rates in Mexican Latinos compared to non-Mexican Latinos (both p < 0.05). The 5-year (77% vs. 80% vs. 95%) and 10-year (63% vs. 65% vs. 86%) biochemical recurrence-free survival rates were shorter for Mexican patients compared to SCA and Caribbean patients. On multivariable analysis, SCA subpopulation status was associated with significantly better OS, and pathologic T stage > T2 was associated with worse biochemical recurrence-free survival. Conclusions: We identified significant differences in prostate cancer outcomes for different Latino subpopulations, underscoring the importance of population disaggregation in this ethnic group.
Cancers. 2026 Mar 23*** epublish ***
Salvador Jaime-Casas, Regina Barragan-Carrillo, Anjaney Kothari, Wesley Yip, Oluwatimilehin Okunowo, Ahmad Imam, Daniel J Lama, Alexander Chehrazi-Raffle, Abhishek Tripathi, Sumanta K Pal, Clayton S Lau, Kevin G Chan, Ali Zhumkhawala, Jonathan Yamzon, Tanya Dorff, Bertram Yuh
Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA., Instituto Nacional de Cancerologia (INCAN), Mexico City 14080, Mexico., Division of Biostatistics, Department of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA., Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.